[Form 3] NovaBridge Biosciences Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

NovaBridge Biosciences director Au Chun Kwok Alan has reported his derivative equity holdings in a new Form 3. He holds a 2024 Employee Share Option covering 114,093 Ordinary Shares at an exercise price of 1.2200 per share, expiring on October 1, 2034, which is fully vested and exercisable.

He also holds a 2025 Employee Share Option covering 34,530 underlying Ordinary Shares at an exercise price of 3.8600, expiring on October 1, 2035, which vests in full on the first anniversary of the October 1, 2025 grant date. Footnotes note that Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares, and that the underlying amounts and exercise prices are expressed in ADS terms.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Au Chun Kwok Alan

Role Director

Type	Security	Shares	Price	Value
holding	2024 Employee Share Option (right to buy)	--	--	--
holding	2025 Employee Share Option (right to buy)	--	--	--

Holdings After Transaction: 2024 Employee Share Option (right to buy) — 114,093 shares (Direct); 2025 Employee Share Option (right to buy) — 34,530 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Number of underlying securities and exercise price expressed in terms of ADSs. The option was granted on October 1, 2024 and is fully vested and exercisable. The option was granted on October 1, 2025. The option vests and becomes exercisable in full on the first anniversary of the grant date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Au Chun Kwok Alan

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2024 Employee Share Option (right to buy)	(3)	10/01/2034	Ordinary Shares(1)	114,093(2)	$1.22(2)	D
2025 Employee Share Option (right to buy)	(4)	10/01/2035	Ordinary Shares(1)	34,530(2)	$3.86(2)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Number of underlying securities and exercise price expressed in terms of ADSs.

3. The option was granted on October 1, 2024 and is fully vested and exercisable.

4. The option was granted on October 1, 2025. The option vests and becomes exercisable in full on the first anniversary of the grant date.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)